Home / Health / Alzheimer's Blood Test: Misfolding Key?
Alzheimer's Blood Test: Misfolding Key?
29 Jul
Summary
- Protein misfolding biomarker shows earlier Alzheimer's risk.
- P-tau 217 less predictive before symptoms emerge.
- Combined biomarkers offer highly accurate early prediction.
New research indicates that protein misfolding biomarkers may identify Alzheimer's disease risk earlier than the widely used P-tau 217 blood test. While P-tau 217 is highly effective once symptoms appear, its predictive power is moderate before cognitive decline. The study found that a biomarker detecting amyloid beta protein misfolding had better predictive capabilities in asymptomatic individuals.
Researchers combined the misfolding marker with demographic data and genetic factors. This panel achieved a high accuracy score, suggesting potential for predicting Alzheimer's diagnosis years before symptoms manifest. This development is crucial as disease-modifying therapies, intended for early symptomatic stages, become available.
Experts emphasize that Alzheimer's is influenced by multiple factors, including vascular health and genetics. They suggest that protein misfolding might represent the earliest measurable blood-based marker. However, further evidence in diverse populations and clear guidelines for testing are needed before widespread clinical adoption.
Obstacles to routine testing include regulatory approval from bodies like the FDA and EMA. Experts also caution about the psychological impact of knowing one's risk years in advance. These new blood tests are not definitive diagnoses, and patients must understand their limitations.
